Asabys has today announced its first investment from its new SAHII II in our client DeepUll, that develops novel diagnostic solutions for Sepsis, among other acute infections.

Asabys joins  the existing investors in Deepull. Werfen, Innvierte (CDTI), Kurma Partners, Alta Life sciences, UI Investissement and Axis Participaciones Empresariales that together backed the current Series B in DeepUll, announced in October 2022 for €13M and that now grows to €17M.